Search

Your search keyword '"Eloy Rodríguez-Rodríguez"' showing total 2 results
Start Over Author "Eloy Rodríguez-Rodríguez" Journal journal of the neurological sciences
2 results on '"Eloy Rodríguez-Rodríguez"'

1. Interaction between CD14 and LXRβ genes modulates Alzheimer's disease risk

Author

José Berciano, Onofre Combarros, Eloy Rodríguez-Rodríguez, Ignacio Mateo, Inés García-Gorostiaga, Jon Infante, Coro Sánchez-Quintana, and Pascual Sánchez-Juan

Subjects
Genetic Markers, Male, medicine.medical_specialty, Genotype, CD14, DNA Mutational Analysis, Lipopolysaccharide Receptors, Receptors, Cytoplasmic and Nuclear, Biology, Alzheimer Disease, Monitoring, Immunologic, Polymorphism (computer science), Internal medicine, medicine, Humans, Genetic Predisposition to Disease, Genetic Testing, Gliosis, Risk factor, Liver X receptor, Aged, Liver X Receptors, Aged, 80 and over, Polymorphism, Genetic, Innate immune system, Microglia, Neurodegeneration, Brain, Middle Aged, Orphan Nuclear Receptors, medicine.disease, Immunity, Innate, Introns, DNA-Binding Proteins, medicine.anatomical_structure, Endocrinology, Neurology, Case-Control Studies, Immunology, Encephalitis, Female, Neurology (clinical), Alzheimer's disease
Abstract

A chronic inflammatory process with activation of microglial cells contribute to the neurodegeneration associated with Alzheimer's disease (AD). CD14 and LXRβ are receptors involved in the regulation of inflammatory responses of microglia in response to bacterial infection or lipopolysaccharide stimulation. In a case–control study in 266 AD patients and 273 healthy controls, we examined whether the combined gene effects between CD14 (− 260) polymorphism and LXRβ (intron 5) polymorphism might be responsible for susceptibility to AD. Subjects carrying both the CD14 (− 260) C/C and the LXRβ (intron 5) G/G genotypes had a six times lower risk of developing AD than subjects without these risk genotypes (OR 0.16, 95% CI 0.04–0.67, p = 0.01). These data support a role for innate immune response genes in risk for AD.

Published
2008
Full Text
View/download PDF

2. Poly (ADP-ribose) polymerase-1 (PARP-1) genetic variants are protective against Parkinson's disease

Author

Javier Llorca, Eloy Rodríguez-Rodríguez, Pascual Sánchez-Juan, Onofre Combarros, Agustín Oterino, José Berciano, Ana Fontalba, Jon Infante, Coro Sánchez-Quintana, Ignacio Mateo, and Jesús Mª. Terrazas

Subjects
Adult, Male, Heterozygote, Parkinson's disease, Poly ADP ribose polymerase, Poly (ADP-Ribose) Polymerase-1, Biology, Loss of heterozygosity, Genetic variation, medicine, Odds Ratio, Humans, Age of Onset, Promoter Regions, Genetic, Gene, Aged, Genetics, Aged, 80 and over, Genetic Variation, Promoter, Parkinson Disease, Middle Aged, medicine.disease, Neurology, Case-Control Studies, Microsatellite, Female, Neurology (clinical), Age of onset, Poly(ADP-ribose) Polymerases, Microsatellite Repeats
Abstract

Poly (ADP-ribose) polymerase-1 (PARP-1) is involved in crucial pathogenic events in Parkinson's disease (PD). We studied the effect of promoter variations of PARP-1 gene on the risk for PD in a case-control association study comprising 146 PD patients and 161 controls from Northern Spain. Three polymorphisms from the promoter region of PARP-1 gene were analyzed: -410C/T, -1672G/A, and a (CA)n microsatellite. A protective effect against PD was found for heterozygosity at (-410) (OR 0.44) and (CA)n microsatellite (OR 0.53) polymorphisms, and heterozygosity at (-1672) polymorphism delayed by 4 years on the onset age of PD. Variations in the regulatory region of PARP-1 gene might modify the risk for PD.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results